Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Change in Accured Expenses (2019 - 2025)

C4 Therapeutics (CCCC) has 7 years of Change in Accured Expenses data on record, last reported at $2.1 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 47.95% year-over-year to $2.1 million; the TTM value through Dec 2025 reached -$6.0 million, down 377.43%, while the annual FY2025 figure was -$6.0 million, 377.43% down from the prior year.
  • Change in Accured Expenses reached $2.1 million in Q4 2025 per CCCC's latest filing, up from -$2.0 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $5.2 million in Q4 2023 and bottomed at -$7.7 million in Q1 2024.
  • Average Change in Accured Expenses over 5 years is $173000.0, with a median of $1.3 million recorded in 2021.
  • The widest YoY moves for Change in Accured Expenses: up 669.17% in 2024, down 426.07% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at $2.1 million in 2021, then grew by 26.09% to $2.7 million in 2022, then surged by 92.5% to $5.2 million in 2023, then fell by 23.29% to $4.0 million in 2024, then crashed by 47.95% to $2.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $2.1 million in Q4 2025, -$2.0 million in Q3 2025, and $627000.0 in Q2 2025.